Acumen Pharmaceuticals, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 26, 2024. This is an annual report, not a standalone fourth-quarter report. Acumen is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its principal program is sabirnetug (ACU193), an investigational antibody for early Alzheimer’s disease.
Financial results and liquidity
| Metric | FY 2023 | FY 2022 | Change |
|---|---|---|---|
| Revenue from product sales | None | None | No commercial product revenue |
| Research and development expense | $42.3 million | $32.4 million | Up 31% |
| General and administrative expense | $18.8 million | $12.9 million | Up 46% |
| Total operating expenses | $61.1 million | $45.2 million | Up 35% |
| Net loss | $52.4 million | $42.9 million | Loss widened 22% |
| Net loss per share, basic and diluted | $1.08 | $1.06 | Loss per share increased |
| Net cash used in operating activities | $43.1 million | $35.2 million | Use increased $7.9 million |
R&D represented approximately 81% of the 2023 net loss. Higher personnel, contractor and consulting, license, and clinical-development costs drove expense growth. Interest income rose to $10.8 million from $2.4 million, largely reflecting larger investments and higher rates; total other income was $8.8 million.
At year-end, cash and cash equivalents were $66.9 million and marketable securities were $239.2 million, for a combined $306.1 million. Working capital was $233.6 million, versus $172.5 million a year earlier. Management estimates existing cash and marketable securities can fund operating and capital requirements into the first half of 2027, based on its current plan and assumptions.
Debt included a $30.0 million first borrowing under a K2 HealthVentures facility of up to $50.0 million; the additional $20.0 million is subject to lender review and discretionary approval. The facility bears interest at the greater of 9.65% or prime plus 1.15%, with monthly principal and interest payments scheduled to begin July 2026 and maturity in November 2027, potentially extendable to November 2028 if specified financing milestones are met. Year-end long-term debt, net, was $29.9 million. The loan is secured by substantially all assets except intellectual property and includes restrictive covenants.
Cash flows reflect substantial investment in securities: investing activities used $171.7 million in 2023, compared with $39.2 million provided in 2022. Financing provided $151.8 million, principally from the $121.9 million net proceeds of a July 2023 stock offering and $29.5 million net loan proceeds. In January 2024, the company raised a further $7.9 million net through its at-the-market program.
Business progress, changes, and outlook
- INTERCEPT-AD Phase 1: Completed in 2023; 65 participants enrolled and 62 received at least one dose. The company reported that the trial met its primary and secondary objectives. Sabirnetug was described as well tolerated; ARIA-E occurred in 10.4% of participants, including one symptomatic case. ARIA-H occurred in 8.3%.
- The company reported dose-related target engagement and reductions in amyloid PET plaque measures at higher doses. Some CSF biomarker changes were exploratory; the trial was small and short and did not show discernible immediate effects on exploratory cognition or cerebral-blood-flow measures. Phase 1 findings do not establish clinical efficacy.
- ALTITUDE-AD: Management expected to start a placebo-controlled Phase 2 study in the first half of 2024, with up to 540 participants and iADRS at 18 months as the intended primary outcome. The filing describes planned doses of 35 mg/kg and 50 mg/kg every four weeks in its business and MD&A sections, but elsewhere refers to 30 mg/kg and 50 mg/kg. Management also anticipated changing the planned Phase 2/3 design to a standalone Phase 2 study following EMA feedback; any interim analysis could inform a later confirmatory Phase 3 trial.
- Subcutaneous formulation: A November 2023 Halozyme license and collaboration supports development of a subcutaneous formulation. Management expected a Phase 1 study in mid-2024. The agreement includes upfront, development and commercial milestone payments and single-digit royalties; the upfront payment was made in January 2024.
- The company also reported FDA Fast Track designation for sabirnetug, granted in October 2022, and an October 2023 FDA meeting to discuss ALTITUDE-AD design and a potential registration pathway. Fast Track does not assure approval or a faster review.
Management expects expenses and operating losses to rise as clinical development advances. Acumen has one product candidate, has never been profitable, and expects to require substantial additional funding to complete development and pursue commercialization. It may seek equity or debt financing, collaborators, or licensing arrangements; funding may be unavailable or dilute shareholders or impose additional restrictions.
Key risks and notable items
- Clinical and regulatory risk: Sabirnetug remains early in development. Later trials may not confirm Phase 1 findings, demonstrate benefit, or support regulatory approval. Safety, enrollment, protocol changes, manufacturing, and regulator requirements could delay or stop development.
- Funding and debt: The stated runway depends on management’s assumptions and spending could rise faster than expected. The undrawn loan tranche is not assured. Variable interest, repayment obligations, covenants, and potential default could constrain operations.
- Competition and market access: Approved and developing Alzheimer’s therapies compete for patients and clinical-trial sites. Coverage, reimbursement, pricing, and physician or patient acceptance of any future product are uncertain.
- Manufacturing and reliance on third parties: The company relies on contract manufacturers and research organizations and does not own manufacturing facilities. Disruptions, quality issues, or difficulty scaling supply could delay trials or commercialization.
- Intellectual property: The licensed sabirnetug patent portfolio includes one issued U.S. patent and 18 foreign patents, projected to expire in July 2031 before any possible extensions. Patent scope, validity, enforcement, and licensing rights remain risks.
- Unusual financing accounting: The loan includes embedded conversion features measured as derivatives; their reported fair value was $2.6 million at year-end, with a $1.4 million 2023 fair-value expense. The loan also included a warrant for 730,769 shares at $1.95 per share.
- Other disclosures: The company reported no material pending legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal-control effectiveness because of the company’s filer status.
Investor verification points
- Confirm ALTITUDE-AD’s actual start, final protocol, dosing arms, enrollment, primary endpoint, and any regulatory changes; reconcile the filing’s 35 mg/kg versus 30 mg/kg dose descriptions.
- Review complete and updated clinical data, including safety, ARIA, target engagement, biomarker findings, and whether larger, longer trials demonstrate meaningful clinical benefit.
- Assess cash use and runway against actual trial spending, and confirm whether the additional $20 million K2 tranche becomes available and on what terms.
- Review the loan’s interest, amortization, conversion and prepayment terms, covenants, and sensitivity of derivative valuations; note that the filing reports differing interest-expense figures in its MD&A table and debt note.
- Evaluate potential dilution from future equity financing, outstanding options and warrants, and the company’s ability to fund later-stage trials and commercialization.
- Verify the scope and expected duration of sabirnetug patent and regulatory exclusivity, as well as the commercial implications of competition and reimbursement restrictions.